Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.51 USD | -0.12% | -36.02% | -17.46% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.46% | 24Cr | |
+12.06% | 23TCr | |
+12.07% | 19TCr | |
+13.88% | 14TCr | |
+27.12% | 11TCr | |
+0.91% | 6.36TCr | |
+6.74% | 5.13TCr | |
+13.39% | 5.1TCr | |
+8.81% | 4.33TCr | |
+4.14% | 3.7TCr |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Lowers NeuroPace's Price Target to $6 From $9, Maintains Underweight Rating